Overview

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Status:
Terminated
Trial end date:
2016-09-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Pfizer